|
CN105177091A
(zh)
|
2006-03-31 |
2015-12-23 |
中外制药株式会社 |
用于纯化双特异性抗体的抗体修饰方法
|
|
CA2647846C
(en)
|
2006-03-31 |
2016-06-21 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
|
CN106519025B
(zh)
|
2007-09-26 |
2021-04-23 |
中外制药株式会社 |
利用cdr的氨基酸取代来改变抗体等电点的方法
|
|
CA2721052C
(en)
|
2008-04-11 |
2023-02-21 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
CA2787376A1
(en)
|
2010-01-19 |
2011-07-28 |
President And Fellows Of Harvard College |
Engineered opsonin for pathogen detection and treatment
|
|
RU2015102845A
(ru)
*
|
2010-02-23 |
2015-06-10 |
Санофи |
АНТИТЕЛА К ИНТЕГРИНУ α2 И ИХ ПРИМЕНЕНИЯ
|
|
EP3029066B1
(en)
|
2010-07-29 |
2019-02-20 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
|
UY33578A
(es)
|
2010-08-31 |
2012-03-30 |
Sanofi Sa |
PÉPTIDO O COMPLEJO PEPTÍDICO QUE SE UNE A INTEGRINA a(ALFA) Y MÉTODOS Y USOS QUE IMPLICAN A LOS MISMOS
|
|
RU2604490C2
(ru)
|
2010-11-05 |
2016-12-10 |
Займворкс Инк. |
ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ
|
|
TWI807362B
(zh)
|
2010-11-30 |
2023-07-01 |
日商中外製藥股份有限公司 |
細胞傷害誘導治療劑
|
|
BR112013013354A2
(pt)
|
2010-11-30 |
2020-10-06 |
Chugai Seiyaku Kabushiki Kaisha |
molécula de ligação ao antígeno capaz de se ligar a uma pluralidade de moléculas de antígeno repetidamente
|
|
BR112013016235B1
(pt)
*
|
2010-12-22 |
2020-03-31 |
Cephalon Australia Pty Ltd |
Anticorpo isolado, uso de um anticorpo, ácido nucleico, célula transformada e composição farmacêutica
|
|
EP2679681B2
(en)
|
2011-02-25 |
2023-11-15 |
Chugai Seiyaku Kabushiki Kaisha |
FcgammaRIIB-specific FC antibody
|
|
KR20140059168A
(ko)
|
2011-04-21 |
2014-05-15 |
더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 |
시신경 척수염 치료용 조성물 및 치료 방법
|
|
US9228003B2
(en)
*
|
2011-05-05 |
2016-01-05 |
Wellstat Immuno Therapeutics, Llc |
Complement factor B analogs and their uses
|
|
ES2828482T3
(es)
|
2011-06-13 |
2021-05-26 |
Csl Ltd |
Anticuerpos contra el g-csfr y su uso
|
|
EP4011913A1
(en)
|
2011-06-30 |
2022-06-15 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimerized polypeptide
|
|
WO2013012924A2
(en)
|
2011-07-18 |
2013-01-24 |
President And Fellows Of Harvard College |
Engineered microbe-targeting molecules and uses thereof
|
|
AU2012289001B2
(en)
|
2011-07-22 |
2016-03-03 |
Csl Behring Gmbh |
Inhibitory anti -factor XII/XIIa monoclonal antibodies and their uses
|
|
EP2548892A1
(en)
|
2011-07-22 |
2013-01-23 |
CSL Behring GmbH |
Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses
|
|
TWI681970B
(zh)
|
2011-09-30 |
2020-01-11 |
日商中外製藥股份有限公司 |
包含依離子濃度之條件對抗原之結合活性會改變之抗原結合分域、及於pH中性之條件下對FcRn有結合活性之FcRn結合分域、且誘導對標的抗原的免疫反應之抗原結合分子
|
|
TW201326209A
(zh)
*
|
2011-09-30 |
2013-07-01 |
Chugai Pharmaceutical Co Ltd |
具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
|
|
JP6322411B2
(ja)
|
2011-09-30 |
2018-05-09 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
WO2013065708A1
(ja)
|
2011-10-31 |
2013-05-10 |
中外製薬株式会社 |
重鎖と軽鎖の会合が制御された抗原結合分子
|
|
EP2773671B1
(en)
|
2011-11-04 |
2021-09-15 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the fc domain
|
|
CN104080909A
(zh)
|
2011-11-30 |
2014-10-01 |
中外制药株式会社 |
包含进入细胞内以形成免疫复合体的搬运体(载体)的药物
|
|
AU2012362217A1
(en)
*
|
2011-12-28 |
2014-07-24 |
Novelmed Therapeutics, Inc. |
Aglycosylated human antibody and fusion protein and uses thereof
|
|
EP2623110A1
(en)
|
2012-01-31 |
2013-08-07 |
CSL Behring GmbH |
Factor XII inhibitors for the treatment of neurological inflammatory disorders
|
|
CN113527469A
(zh)
*
|
2012-02-09 |
2021-10-22 |
中外制药株式会社 |
抗体的Fc区变异体
|
|
HK1207654A1
(en)
|
2012-04-27 |
2016-02-05 |
Bioatla, Llc |
Modified antibody regions and uses thereof
|
|
CA2875989A1
(en)
|
2012-06-08 |
2013-12-12 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
|
WO2014004586A1
(en)
|
2012-06-25 |
2014-01-03 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
|
US9732161B2
(en)
|
2012-06-26 |
2017-08-15 |
Sutro Biopharma, Inc. |
Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
|
LT2867251T
(lt)
*
|
2012-06-29 |
2019-11-25 |
Bristol Myers Squibb Co |
Glikoproteinų agregacijos sumažinimo būdai
|
|
EP2872170A4
(en)
*
|
2012-07-13 |
2016-06-22 |
Zymeworks Inc |
ASYMMETRIC BISPECIFIC HETERODIMERS WITH ANTI-CD3 CONSTRUCTS
|
|
JP6501521B2
(ja)
|
2012-08-24 |
2019-04-17 |
中外製薬株式会社 |
ＦｃγＲＩＩｂ特異的Ｆｃ領域改変体
|
|
US9682934B2
(en)
|
2012-08-31 |
2017-06-20 |
Sutro Biopharma, Inc. |
Modified amino acids
|
|
EP2904093B1
(en)
|
2012-10-03 |
2019-04-10 |
Zymeworks Inc. |
Methods of quantitating heavy and light chain polypeptide pairs
|
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
|
KR102411491B1
(ko)
|
2012-11-28 |
2022-06-22 |
자임워크스 인코포레이티드 |
가공된 면역글로불린 중쇄-경쇄 쌍 및 이들의 용도
|
|
KR102249779B1
(ko)
|
2012-12-27 |
2021-05-07 |
추가이 세이야쿠 가부시키가이샤 |
헤테로이량화 폴리펩티드
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
CA2898100C
(en)
|
2013-01-14 |
2023-10-10 |
Xencor, Inc. |
Novel heterodimeric proteins
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
WO2014113510A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
US9593157B2
(en)
*
|
2013-01-30 |
2017-03-14 |
Vib Vzw |
Chimeric polypeptides comprising G protein-coupled receptors and VHH antibodies
|
|
TWI682941B
(zh)
*
|
2013-02-01 |
2020-01-21 |
美商再生元醫藥公司 |
含嵌合恆定區之抗體
|
|
SG11201505762XA
(en)
|
2013-02-07 |
2015-08-28 |
Csl Ltd |
Il-11r binding proteins and uses thereof
|
|
CA2901225C
(en)
|
2013-03-08 |
2023-09-19 |
Csl Behring Gmbh |
Treatment and prevention of remote ischemia-reperfusion injury
|
|
US9546203B2
(en)
*
|
2013-03-14 |
2017-01-17 |
Amgen Inc. |
Aglycosylated Fc-containing polypeptides with cysteine substitutions
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
US9657105B2
(en)
|
2013-03-15 |
2017-05-23 |
City Of Hope |
CD123-specific chimeric antigen receptor redirected T cells and methods of their use
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
WO2014144325A1
(en)
|
2013-03-15 |
2014-09-18 |
President And Fellows Of Harvard College |
Methods and compositions for improving detection and/or capture of a target entity
|
|
CA2903587C
(en)
*
|
2013-03-15 |
2021-09-28 |
Genentech, Inc. |
Il-22 polypeptides and il-22 fc fusion proteins and methods of use
|
|
EP3421495A3
(en)
|
2013-03-15 |
2019-05-15 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
CA2908350C
(en)
|
2013-04-02 |
2023-08-08 |
Futa Mimoto |
Fc region variant
|
|
EP3848045A1
(en)
|
2013-05-21 |
2021-07-14 |
President and Fellows of Harvard College |
Engineered heme-binding compositions and uses thereof
|
|
MY199321A
(en)
|
2013-05-30 |
2023-10-24 |
Kiniksa Pharmaceuticals Ltd |
Oncostatin m receptor antigen binding proteins
|
|
KR101895634B1
(ko)
|
2013-05-31 |
2018-09-05 |
한미약품 주식회사 |
변이된 힌지 영역을 포함하는 IgG4 Fc 단편
|
|
EP3019522B1
(en)
|
2013-07-10 |
2017-12-13 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
|
PL3074424T3
(pl)
|
2013-11-27 |
2025-06-09 |
Zymeworks Bc Inc. |
Bispecyficzne konstrukty wiążące antygen ukierunkowane na her2
|
|
WO2015095604A2
(en)
|
2013-12-18 |
2015-06-25 |
President And Fellows Of Harvard College |
Methods and assays relating to circulating tumor cells
|
|
EP3094348B1
(en)
|
2014-01-14 |
2025-03-05 |
AbVacc, Inc. |
Targeting immunological functions to the site of bacterial infections using cell wall targeting domains of bacteriolysins
|
|
WO2015132365A1
(en)
*
|
2014-03-05 |
2015-09-11 |
Ucb Biopharma Sprl |
Multimeric fc proteins
|
|
TW201619188A
(zh)
|
2014-03-05 |
2016-06-01 |
優稀美生物醫藥公司 |
多聚體Ｆｃ蛋白質
|
|
TWI754319B
(zh)
|
2014-03-19 |
2022-02-01 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
|
MX385936B
(es)
|
2014-03-28 |
2025-03-11 |
Xencor Inc |
Anticuerpos biespecíficos que se unen a cd38 y cd3.
|
|
MX380176B
(es)
*
|
2014-04-07 |
2025-03-12 |
Chugai Pharmaceutical Co Ltd |
Molecula ligada a antigeno inmunoactivada.
|
|
NO2776305T3
(enExample)
*
|
2014-04-23 |
2018-01-27 |
|
|
|
ES2962694T3
(es)
|
2014-05-02 |
2024-03-20 |
Momenta Pharmaceuticals Inc |
Composiciones y procedimientos relacionados con construcciones de Fc manipuladas
|
|
CN106459954A
(zh)
|
2014-05-13 |
2017-02-22 |
中外制药株式会社 |
用于具有免疫抑制功能的细胞的t细胞重定向的抗原结合分子
|
|
BR112016027888A2
(pt)
|
2014-05-28 |
2017-10-24 |
Zymeworks Inc |
construto de polipeptídeo de ligação ao antígeno isolado, polinucleotídeo isolado ou um conjunto de polinucleotídeos isolados, vetor ou conjunto de vetores, célula isolada, composição farmacêutica, uso do construto, método para tratar um sujeito com uma doença ou distúrbio, método para obter um construto, método para preparar um construto, meio de armazenamento legível por computador, método para produzir um construto de polipeptídeo de ligação com antígeno bi-específico e método para preparar um construto de polipeptídeo de ligação com antígeno isolado
|
|
US9616114B1
(en)
|
2014-09-18 |
2017-04-11 |
David Gordon Bermudes |
Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
MA40835A
(fr)
|
2014-10-23 |
2017-08-29 |
Biogen Ma Inc |
Anticorps anti-gpiib/iiia et leurs utilisations
|
|
MA40861A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Anticorps anti-glycoprotéines iib/iiia
|
|
EP3699198B1
(en)
|
2014-11-17 |
2025-03-26 |
Regeneron Pharmaceuticals, Inc. |
Methods for tumor treatment using cd3xcd20 bispecific antibody
|
|
MX2017006918A
(es)
|
2014-11-26 |
2018-01-25 |
Xencor Inc |
Anticuerpos heterodimericos que se unen a cd3 y cd38.
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
HRP20211273T1
(hr)
|
2014-11-26 |
2021-11-12 |
Xencor, Inc. |
Heterodimerna protutijela koja vežu cd3 i cd20
|
|
US10940212B2
(en)
|
2014-12-19 |
2021-03-09 |
Monash University |
IL-21 agonist antibodies and methods of treatment using same
|
|
MY181199A
(en)
|
2014-12-19 |
2020-12-21 |
Chugai Pharmaceutical Co Ltd |
Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
|
|
EP3237449A2
(en)
|
2014-12-22 |
2017-11-01 |
Xencor, Inc. |
Trispecific antibodies
|
|
MA41459A
(fr)
*
|
2015-02-03 |
2017-12-12 |
Als Therapy Development Inst |
Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
|
|
CN107108729A
(zh)
*
|
2015-02-05 |
2017-08-29 |
中外制药株式会社 |
包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il‑8‑结合抗体，及其应用
|
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
DK3277725T3
(da)
|
2015-03-30 |
2021-01-11 |
Regeneron Pharma |
Konstante tungkædeområder med reduceret binding til FC-gammareceptorer
|
|
US10676723B2
(en)
|
2015-05-11 |
2020-06-09 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
AU2016297862C1
(en)
|
2015-07-24 |
2022-12-15 |
Gliknik Inc. |
Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin Fc compositions with enhanced complement binding
|
|
WO2017024114A1
(en)
|
2015-08-06 |
2017-02-09 |
President And Fellows Of Harvard College |
Improved microbe-binding molecules and uses thereof
|
|
TWI603980B
(zh)
*
|
2015-09-01 |
2017-11-01 |
免疫功坊股份有限公司 |
用以治療病理性血栓的聯合接合物構型藥物
|
|
AR106365A1
(es)
*
|
2015-10-02 |
2018-01-10 |
Hoffmann La Roche |
Moléculas biespecíficas de unión a antígeno activadoras de células t
|
|
RS66622B1
(sr)
|
2015-10-08 |
2025-04-30 |
Zymeworks Bc Inc |
Antigen-vezujući polipeptidni konstrukti koji sadrže kapa i lambda lake lance, i njihove upotrebe
|
|
AU2016347688A1
(en)
|
2015-10-30 |
2018-06-21 |
The University Of Melbourne |
Methods and compositions for improving glucose metabolism
|
|
EP3378488A4
(en)
|
2015-11-18 |
2019-10-30 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD FOR IMPROVING THE HUMORAL IMMUNE REACTION
|
|
US11660340B2
(en)
|
2015-11-18 |
2023-05-30 |
Chugai Seiyaku Kabushiki Kaisha |
Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
|
|
BR112018010766A8
(pt)
|
2015-11-27 |
2019-02-26 |
Csl Ltd |
proteínas de ligação ao cd131 e usos das mesmas
|
|
JP7058219B2
(ja)
|
2015-12-07 |
2022-04-21 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体
|
|
CA3004288C
(en)
|
2015-12-28 |
2025-05-27 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD FOR PROMOTING THE CLEARANCE EFFICIENCY OF A POLYPEPTIDE CONTAINING THE FC REGION
|
|
CA3011455A1
(en)
|
2016-01-27 |
2017-08-03 |
Sutro Biopharma, Inc. |
Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
|
|
ES2972740T3
(es)
|
2016-03-02 |
2024-06-14 |
Momenta Pharmaceuticals Inc |
Procedimientos relacionados con construcciones de Fc modificadas genéticamente
|
|
BR112018068363A2
(pt)
|
2016-03-14 |
2019-01-15 |
Chugai Seiyaku Kabushiki Kaisha |
fármaco terapêutico indutor de dano celular para uso em terapia de câncer
|
|
IL263213B2
(en)
|
2016-05-23 |
2024-05-01 |
Momenta Pharmaceuticals Inc |
Compositions and methods related to engineered fc constructs
|
|
FI3468586T3
(fi)
|
2016-06-14 |
2024-10-29 |
Xencor Inc |
Bispesifisiä immuuniaktivaatiota vapauttavia vasta-aineita
|
|
EP3475304B1
(en)
|
2016-06-28 |
2022-03-23 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
|
US20190389941A1
(en)
*
|
2016-07-22 |
2019-12-26 |
Gliknik Inc. |
Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced fc receptor binding
|
|
KR20250036943A
(ko)
|
2016-08-02 |
2025-03-14 |
비스테라, 인크. |
조작된 폴리펩티드 및 그의 용도
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
CA3040504A1
(en)
|
2016-10-14 |
2018-04-19 |
Xencor, Inc. |
Il15/il15ra heterodimeric fc-fusion proteins
|
|
CA3042989A1
(en)
|
2016-11-07 |
2018-05-11 |
Junho Chung |
Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
|
|
US11180535B1
(en)
|
2016-12-07 |
2021-11-23 |
David Gordon Bermudes |
Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
|
|
US11129906B1
(en)
|
2016-12-07 |
2021-09-28 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
KR20190093186A
(ko)
|
2016-12-09 |
2019-08-08 |
글리크닉 인코포레이티드 |
다가 Fc 화합물에 의해 염증성 장애를 치료하는 방법
|
|
EP3565588A4
(en)
|
2017-01-06 |
2020-12-16 |
Momenta Pharmaceuticals, Inc. |
COMPOSITIONS AND METHODS RELATING TO MODIFIED FC CONSTRUCTIONS
|
|
EP3568159A4
(en)
|
2017-01-11 |
2020-08-05 |
Bristol-Myers Squibb Company |
PSGL-1 ANTAGONISTS AND THEIR USES
|
|
PE20191708A1
(es)
*
|
2017-03-14 |
2019-11-28 |
Five Prime Therapeutics Inc |
ANTICUERPOS DE UNION A VISTA A pH ACIDO
|
|
US11384152B2
(en)
*
|
2017-05-24 |
2022-07-12 |
Als Therapy Development Institute |
Therapeutic anti-CD40 ligand antibodies
|
|
EP3645563A4
(en)
|
2017-06-27 |
2021-03-17 |
Neuracle Science Co., Ltd |
ANTI-FAM19A5 ANTIBODIES AND USES THEREOF
|
|
AU2018291081B2
(en)
|
2017-06-27 |
2025-02-20 |
Neuracle Science Co., Ltd. |
Use of anti-FAM19A5 antibodies for treating cancers
|
|
EP3645039A4
(en)
|
2017-06-27 |
2021-05-05 |
Neuracle Science Co., Ltd |
USE OF ANTI-FAM19A5 ANTIBODIES TO TREAT FIBROSIS
|
|
US11746149B2
(en)
|
2017-06-27 |
2023-09-05 |
Neuracle Science Co., Ltd. |
Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of glaucoma
|
|
MA49517A
(fr)
|
2017-06-30 |
2020-05-06 |
Xencor Inc |
Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène
|
|
EP3692171A4
(en)
|
2017-10-02 |
2021-06-23 |
Neuracle Science Co., Ltd |
USING ANTI-FAMILY WITH SEQUENCE LIKE 19, ELEMENT A5 ANTIBODIES FOR TREATMENT AND DIAGNOSIS OF MENTAL DISORDERS
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
WO2019094637A1
(en)
|
2017-11-08 |
2019-05-16 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-pd-1 sequences
|
|
US20210179721A1
(en)
|
2017-11-29 |
2021-06-17 |
Csl Limited |
Method of treating or preventing ischemia-reperfusion injury
|
|
KR102722731B1
(ko)
|
2017-12-19 |
2024-10-25 |
젠코어 인코포레이티드 |
조작된 il-2 fc 융합 단백질
|
|
KR20250154550A
(ko)
|
2018-03-21 |
2025-10-28 |
파이브 프라임 테라퓨틱스, 인크. |
산성 pH에서 VISTA에 결합하는 항체
|
|
WO2019178645A1
(en)
|
2018-03-23 |
2019-09-26 |
Csl Limited |
Method of treating asthma
|
|
GB201814562D0
(en)
|
2018-09-07 |
2018-10-24 |
Hummingbird Bioscience Pte Ltd |
Vista antigen-binding molecules
|
|
CN112469477A
(zh)
|
2018-04-04 |
2021-03-09 |
Xencor股份有限公司 |
与成纤维细胞活化蛋白结合的异源二聚体抗体
|
|
JP2021521784A
(ja)
|
2018-04-18 |
2021-08-30 |
ゼンコア インコーポレイテッド |
ＩＬ−１５／ＩＬ−１５ＲａＦｃ融合タンパク質とＰＤ−１抗原結合ドメインを含むＰＤ−１標的化ヘテロダイマー融合タンパク質およびそれらの使用
|
|
CA3097741A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
|
CN119607195A
(zh)
|
2018-04-24 |
2025-03-14 |
纽洛可科学有限公司 |
抗序列相似家族19成员a5的抗体在治疗神经性疼痛中的用途
|
|
EP3790979A4
(en)
|
2018-05-08 |
2022-04-27 |
Neuracle Science Co., Ltd |
RELEASE OF ADENO-ASSOCIATED VIRUS (AAV) FROM ANTI-FAM19A5 ANTIBODIES
|
|
US11970532B2
(en)
|
2018-05-10 |
2024-04-30 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
|
|
CN119080931A
(zh)
*
|
2018-06-04 |
2024-12-06 |
马萨诸塞州渤健公司 |
具有降低的效应功能的抗vla-4抗体
|
|
WO2020003210A1
(en)
|
2018-06-29 |
2020-01-02 |
Kangwon National University University-Industry Cooperation Foundation |
Anti-l1cam antibodies and uses thereof
|
|
JP7700036B2
(ja)
|
2018-07-11 |
2025-06-30 |
ファイヴ プライム セラピューティクス インク |
酸性ｐＨでＶＩＳＴＡと結合する抗体
|
|
AU2019309472A1
(en)
*
|
2018-07-24 |
2021-03-18 |
Good T Cells, Inc. |
Composition for preventing or treating immune-related diseases
|
|
DK3844189T3
(da)
|
2018-08-31 |
2025-02-24 |
Regeneron Pharma |
Doseringsstrategi, der mindsker cytokinfrigivelsessyndrom for CD3/CD20-bispecifikke antistoffer
|
|
SG11202103192RA
(en)
|
2018-10-03 |
2021-04-29 |
Xencor Inc |
Il-12 heterodimeric fc-fusion proteins
|
|
JP7211610B2
(ja)
|
2018-10-16 |
2023-01-24 |
ニューラクル サイエンス カンパニー リミテッド |
抗ｆａｍ１９ａ５抗体の用途
|
|
AU2019371814A1
(en)
|
2018-10-29 |
2021-06-17 |
Biogen Ma Inc. |
Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport
|
|
JP7315256B2
(ja)
|
2018-12-05 |
2023-07-26 |
ヘッジホッグ，インコーポレイテッド |
エンドセリン受容体ａ活性調節抗体
|
|
CN113227139B
(zh)
|
2018-12-27 |
2024-10-29 |
纽洛可科学有限公司 |
抗fam19a5抗体治疗动脉粥样硬化的用途
|
|
KR102656738B1
(ko)
|
2019-01-02 |
2024-04-16 |
주식회사 뉴라클사이언스 |
항-서열 유사성 19를 가진 패밀리, 멤버 a5 항체 및 이의 사용 방법
|
|
MX2021010390A
(es)
|
2019-03-01 |
2021-11-17 |
Xencor Inc |
Anticuerpos heterodimericos que se unen a enpp3 y cd3.
|
|
WO2020210358A1
(en)
|
2019-04-08 |
2020-10-15 |
Biogen Ma Inc. |
Anti-integrin antibodies and uses thereof
|
|
US12384834B2
(en)
|
2019-05-28 |
2025-08-12 |
The General Hospital Corporation |
Anti-ApoE antibodies and polynucleotides thereof
|
|
SMT202400527T1
(it)
*
|
2019-07-01 |
2025-01-14 |
Tonix Pharma Ltd |
Anticorpi anti-cd154 e loro usi
|
|
CN111257445B
(zh)
*
|
2020-01-22 |
2022-09-09 |
上海交通大学医学院附属仁济医院 |
用于sle孕妇病情监测及其胎儿结局预测的产品及方法
|
|
CA3173064A1
(en)
*
|
2020-02-27 |
2021-09-02 |
Huahui Health Ltd. |
Soluble ace2 and fusion protein, and applications thereof
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
US20230303715A1
(en)
*
|
2020-05-20 |
2023-09-28 |
Zymeworks Bc Inc. |
IMMUNOGLOBULIN Fc REGION VARIANTS COMPRISING STABILITY-ENHANCING MUTATIONS
|
|
EP4454659A3
(en)
|
2020-08-18 |
2025-01-22 |
Cephalon LLC |
Anti-par-2 antibodies and methods of use thereof
|
|
WO2022040482A1
(en)
|
2020-08-19 |
2022-02-24 |
Xencor, Inc. |
Anti-cd28 and/or anti-b7h3 compositions
|
|
CA3206107A1
(en)
|
2021-01-26 |
2022-08-04 |
Brian Furmanski |
Vector constructs for delivery of nucleic acids encoding therapeutic anti-tnf antibodies and methods of using the same
|
|
CN117157319A
(zh)
|
2021-03-09 |
2023-12-01 |
Xencor股份有限公司 |
结合cd3和cldn6的异二聚抗体
|
|
KR20230154311A
(ko)
|
2021-03-10 |
2023-11-07 |
젠코어 인코포레이티드 |
Cd3 및 gpc3에 결합하는 이종이량체 항체
|
|
US20230016731A1
(en)
*
|
2021-05-21 |
2023-01-19 |
The Regents Of The University Of California |
Affinity purification sequencing
|
|
US12448451B2
(en)
|
2021-06-25 |
2025-10-21 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-CTLA-4 antibody and use thereof
|
|
TW202322850A
(zh)
*
|
2021-08-05 |
2023-06-16 |
美商美國禮來大藥廠 |
抗體最佳化
|
|
IL312221A
(en)
|
2021-10-20 |
2024-06-01 |
Synthekine Inc |
Heterodimeric fc cytokines and uses thereof
|
|
EP4460522A1
(en)
|
2022-01-09 |
2024-11-13 |
Kriya Therapeutics, Inc. |
Vector constructs for delivery of nucleic acids encoding therapeutic anti-igf-1r antibodies and methods of using the same
|
|
WO2024054993A1
(en)
|
2022-09-09 |
2024-03-14 |
Kriya Therapeutics, Inc. |
Vector constructs for delivery of nucleic acids encoding therapeutic anti-ctla4 antibodies and methods of using the same
|
|
WO2025007195A1
(en)
|
2023-07-05 |
2025-01-09 |
CSL Innovation Pty Ltd |
Methods of treating or preventing a complication of sickle cell disease
|
|
WO2025014832A1
(en)
|
2023-07-07 |
2025-01-16 |
Kriya Therapeutics, Inc. |
Periocular delivery of aav vectors for treating ophthalmic pathologies
|
|
WO2025171411A1
(en)
|
2024-02-09 |
2025-08-14 |
Herophilus, Inc. |
Compositions and methods related to modulating macrophage migration inhibitory factor (mif)-cd74 signaling and related treatments for neuroinflammatory conditions
|